Cargando…

Differential molecular pathway expression according to chemotherapeutic response in ovarian clear cell carcinoma

OBJECTIVE: Ovarian clear cell carcinoma (OCCC) is a distinct entity from epithelial ovarian cancer. The prognosis of advanced and recurrent disease is very poor due to resistance to chemotherapeutic agents. Our aim was to explore the molecular alterations among OCCC patients with different chemother...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yin, Min, Lu, Chunli, Zhou, Huimei, Liu, Qian, Yang, Jiaxin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10239578/ https://www.ncbi.nlm.nih.gov/pubmed/37270486 http://dx.doi.org/10.1186/s12905-023-02420-1

Ejemplares similares

Fibroblast Growth Factor 11 (FGF11) Promotes Progression and Cisplatin Resistance Through the HIF-1α/FGF11 Signaling Axis in Ovarian Clear Cell Carcinoma
por: Yin, Min, et al.
Publicado: (2023)

Distinct gene expression profiles associated with clinical outcomes in patients with ovarian clear cell carcinoma and high-grade serous ovarian carcinoma
por: Zhou, Huimei, et al.
Publicado: (2020)

Impact of Adjuvant Chemotherapy on FIGO Stage I Ovarian Clear Cell Carcinoma: A Systematic Review and Meta-Analysis
por: Yin, Min, et al.
Publicado: (2022)

Differences in immune-related gene expressions and tumor-infiltrating lymphocytes according to chemotherapeutic response in ovarian high-grade serous carcinoma
por: Choi, Kyung Un, et al.
Publicado: (2020)

The Mitochondrial PHB2/OMA1/DELE1 Pathway Cooperates with Endoplasmic Reticulum Stress to Facilitate the Response to Chemotherapeutics in Ovarian Cancer
por: Cheng, Meiyu, et al.
Publicado: (2022)

Differential expression of estrogen receptor subtypes in ovarian high‐grade serous carcinoma and clear cell carcinoma
por: Osaku, Daiken, et al.
Publicado: (2021)

Profile of differentially expressed miRNAs in high-grade serous carcinoma and clear cell ovarian carcinoma, and the expression of miR-510 in ovarian carcinoma
por: ZHANG, XINCHEN, et al.
Publicado: (2015)

New perspectives on molecular targeted therapy in ovarian clear cell carcinoma
por: Tan, D S P, et al.
Publicado: (2013)

Identification of LEFTY as a molecular marker for ovarian clear cell carcinoma
por: Akiya, Masashi, et al.
Publicado: (2017)

Targeting DNA Damage Response Pathway in Ovarian Clear Cell Carcinoma
por: Wong, Oscar G. W., et al.
Publicado: (2021)

The Effects of Chemotherapeutics on the Ovarian Cancer Microenvironment
por: Eckert, Mark A., et al.
Publicado: (2021)

Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes
por: Bolton, Kelly L., et al.
Publicado: (2022)

Can circulating cell free DNA be a promising marker in ovarian cancer? – a genome-scale profiling study in a single institution
por: Zhou, Huimei, et al.
Publicado: (2023)

The target therapy of ovarian clear cell carcinoma
por: Jin, Ying, et al.
Publicado: (2014)

Preclinical evaluation of an unconventional ruthenium‐gold‐based chemotherapeutic: RANCE‐1, in clear cell renal cell carcinoma
por: Elie, Benelita T., et al.
Publicado: (2019)

Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression
por: Cheasley, Dane, et al.
Publicado: (2022)

Ovarian Clear Cell Carcinoma Sub-Typing by ARID1A Expression
por: Choi, Jae Yoon, et al.
Publicado: (2017)

Pathway Signature and Cellular Differentiation in Clear Cell Renal Cell Carcinoma
por: Tun, Han W., et al.
Publicado: (2010)

Variable CT Findings of Epithelial Origin Ovarian Carcinoma According to the Degree of Histologic Differentiation
por: Jang, Yun-Jin, et al.
Publicado: (2007)

Survival benefit of patients with early-stage ovarian carcinoma treated with paclitaxel chemotherapeutic regimens
por: Chen, Chien-An, et al.
Publicado: (2018)

Updates of Pathogenesis, Diagnostic and Therapeutic Perspectives for Ovarian Clear Cell Carcinoma
por: Zhu, Chenchen, et al.
Publicado: (2021)

Antioxidants and Therapeutic Targets in Ovarian Clear Cell Carcinoma
por: Amano, Tsukuru, et al.
Publicado: (2021)

Long noncoding RNA expression signature to predict platinum-based chemotherapeutic sensitivity of ovarian cancer patients
por: Liu, Rong, et al.
Publicado: (2017)

Current Position of the Molecular Therapeutic Targets for Ovarian Clear Cell Carcinoma: A Literature Review
por: Amano, Tsukuru, et al.
Publicado: (2019)

In vitro sensitivity of human ovarian tumours to chemotherapeutic agents.
por: Wilson, A. P., et al.
Publicado: (1981)

Differential expression of pluripotent and germ cell markers in ovarian surface epithelium according to age in female mice
por: Joo, Bo Sun, et al.
Publicado: (2014)

Over-expression of RALYL suppresses the progression of ovarian clear cell carcinoma through inhibiting MAPK and CDH1 signaling pathways
por: Xia, Ye, et al.
Publicado: (2021)

Tissue factor pathway inhibitor-2 is specifically expressed in ovarian clear cell carcinoma tissues in the nucleus, cytoplasm and extracellular matrix
por: Ota, Yukihide, et al.
Publicado: (2021)

Evidence that p53-Mediated Cell-Cycle-Arrest Inhibits Chemotherapeutic Treatment of Ovarian Carcinomas
por: Moreno, Carlos S., et al.
Publicado: (2007)

Development and external validation of nomograms for predicting individual survival in patients with ovarian clear cell carcinoma
por: Liu, Xiaoshi, et al.
Publicado: (2023)

Prognostic significance and predictors of the system inflammation score in ovarian clear cell carcinoma
por: Zhang, Hongwei, et al.
Publicado: (2017)

Salvage Chemotherapy for Patients With Recurrent or Persistent Ovarian Clear Cell Carcinoma: A Retrospective Study of 164 Cases
por: Bai, Huimin, et al.
Publicado: (2015)

Sonographic features differentiating early-stage ovarian clear cell carcinoma from endometrioma with atypical features
por: Huang, Kuan-Ju, et al.
Publicado: (2022)

Characteristic and Prognostic Implication of Venous Thromboembolism in Ovarian Clear Cell Carcinoma: A 12-Year Retrospective Study
por: Ye, Shuang, et al.
Publicado: (2015)

Preclinical Efficacy and Safety Assessment of Artemisinin-Chemotherapeutic Agent Conjugates for Ovarian Cancer
por: Li, Xiaoguang, et al.
Publicado: (2016)

Establishment and molecular characterization of a human ovarian clear cell carcinoma cell line (FDOV1)
por: Jiang, Wei, et al.
Publicado: (2018)

Magnetic Resonance Imaging Characteristics of Ovarian Clear Cell Carcinoma
por: Wang, Wei, et al.
Publicado: (2015)

Napsin A as a marker of clear cell ovarian carcinoma
por: Skirnisdottir, Ingiridur, et al.
Publicado: (2013)

Unilateral ovarian metastasis from renal clear cell carcinoma
por: Younes, Bencherifi, et al.
Publicado: (2023)

Transcriptomic analyses of ovarian clear-cell carcinoma with concurrent endometriosis
por: Collins, Kaitlyn E., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_h2eqjp0kde1t60nn1g61kjeo93